Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.
Share
Why It Matters
An analyst thinks Revolution Medicines is still a good company to own. They raised their price target by just one dollar, showing steady confidence.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.